|
|
|
| Effects of Pabolizumab on T Lymphocyte and Serum sMICA Levels in Patients with Non-small Cell Lung Cancer |
| Li Lanju, Xu Ensong, Li Wenming, Zhang Nan |
| Nanyang Central Hospital Henan Nanyang,473000,China |
|
|
|
|
Abstract Objective To observe the effects of pabolizumab on T lymphocyte subsets and serum soluble MHC-1 chain related protein A(sMICA)levels in patients with non-small cell lung cancer(NSCLC). Methods 140 patients with NSCLC were treated in our hospital.They were divided by random number table method,70 patients in the control group were treated with AP regimen,and 70 patients in the observation group were treated with palizol.The clinical efficacy of the two groups was compared,the peripheral blood T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)were detected,the serological indicators[squamous cell carcinoma associated antigen(SCC-Ag),carcinoembryonic antigen(CEA),sMICA,Transforming growth factor β1(TGF-β1),Vascular endothelial growth factor(VEGF)] were detected,and the adverse reactions of the two groups were recorded. Results The DCR of the observation group was 84.29%,which was higher than the control group's 67.14%(P<0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+ in observation group were and,which were higher than those in control group and.CD8+ level in observation group was,lower than that in control group,P<0.05.After treatment,the serum levels of SCC-Ag,CEA and sMICA in the observation group were and pg/mL.It was lower than that of control group,P<0.05.After treatment,the levels of TGF-β1 and VEGF in serum were and,which were lower than those in control group(29.03±4.12)μg/L and(377.14±35.98)ng/L,P<0.05.The incidence of adverse reactions was similar between the two groups(P>0.05). Conclusion Pabolizumab can regulate the level of T lymphocyte subsets,reduce the level of tumor markers and serum sMICA in non-small cell lung cancer NSCLC,and has good efficacy and safety.
|
|
Received: 09 April 2025
|
|
|
|
|
|
[1] 薛艳峰. 化疗联合帕博利珠单抗治疗晚期肺腺癌患者20例观察[J].中国药物与临床,2020,20(8):1335-1337.
[2] 卢芳,钱文霞,宣晓峰.非小细胞肺癌血清sMICA、micro RNA-99a、DJ-1表达及临床意义[J].临床肿瘤学杂志,2023,28(6):508-512.
[3] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志,2018,40(12):935-964.
[4] 李益行,赵恒,刘博豪,等.帕博利珠单抗联合新辅助化疗治疗非小细胞肺癌的近期疗效和安全性[J].中国胸心血管外科临床杂志,2023,30(3):369-374.
[5] 陈大卫,JAMES W WELSH.帕博利珠单抗单用或与放疗联用治疗转移性非小细胞肺癌:两个随机试验的汇总分析[J].中华肿瘤防治杂志,2021,28(24):1841-1850.
[6] 储赏奇,贾伟,姜黎黎,等.艾迪注射液联合帕博利珠单抗治疗晚期非小细胞肺癌的临床研究[J].现代药物与临床,2022,37(11):2568-2573.
[7] 许德颖. 帕博利珠单抗联合放化疗治疗晚期非小细胞肺癌患者的临床疗效与安全性[J].实用药物与临床,2022,25(3):232-235.
[8] 陈维英,净卫娟,辛玉珍,等.帕博利珠单抗联合卡铂、白蛋白紫杉醇治疗晚期非小细胞肺癌的疗效及安全性[J].山东医药,2021,61(13):65-68.
[9] 王莹莹. 抗血管生成联合免疫治疗在晚期非小细胞肺癌中的研究进展[J].检验医学与临床,2021,18(20):3052-3055.
[10] 韩强,郑纪红,宋忠全,等.帕博利珠单抗在非小细胞肺癌治疗中的研究进展[J].国际免疫学杂志,2022,45(1):90-95. |
| [1] |
Wang Lidong, Wang Binbin, Duan Zheng, Zhang Juan. Effects of the Addition and Subtraction of Zhenggan Huazheng Tang Together with Western Drug Therapy on Liver Function and T Lymphocyte Subpopulations in Patients with Primary Hepatocellular Carcinoma[J]. journal1, 2024, 44(4): 112-115. |
| [2] |
. [J]. journal1, 2024, 44(3): 122-124. |
| [3] |
. Study on the Expression Level of ki-67 in Non-small Cell Lung Cancer,EGFR Mutation and Clinical Correlation[J]. journal1, 2024, 44(2): 55-56. |
| [4] |
Ding Yanhua, Men Shuai, Zhang Jiangxia, Zhang Xu, Zhang Shancun, Liu Lu, Lv Hongwei, Xiao Zhenghong. Clinical Efficacy of Bevacizumab Combined with Anlotinib in The Treatment of Non-small Cell Lung Cancer and Its Influence on Immune Status[J]. journal1, 2024, 44(1): 41-44. |
| [5] |
Ma Hongwu, Wu Weixuan, Fan Haoqin, Chen Xueyan. Predictive Value of Inflammatory Prognostic Index Combined with IL-11 for Immune Related Adverse Reactions in Advanced Non-small Cell Lung Cancer[J]. journal1, 2023, 43(5): 49-51. |
| [6] |
. [J]. journal1, 2023, 43(2): 63-65. |
|
|
|
|
2025, Vol. 45 
